Clinical Laserthermia Systems AB
14 Feb - 28 Feb 2023Warrant exercise TO 5
Clinical Laserthermia Systems is active in medical technology. The company‘s vision is to develop and streamline the treatment of solid cancer tumors, where the company is a seller of sterile patient kits. The products are used in various cancer treatments such as the treatment of malignant melanoma, as well as cancer of the lungs, liver and pancreas. The company was founded in 2006 and is headquartered in Lund, Sweden
At CLS, they aim at getting doctors as close as possible to the clinical problem and provide the means needed for solving it – without causing another. They do this by providing precise tools for image-guided laser-mediated thermal ablations.
Thermal ablation is used for treatment and removal of diseased or abnormal soft tissues, such as malignant tumors (cancer) or epileptogenic foci. The procedure is minimally invasive and can therefore be offered also to patients that are considered inoperable in view of traditional open surgery.
The offer in summary
Subscription period: 14 February - 28 February 2023
Price per share: SEK 0.46
Trading with warrants: Until 24 February 2023
Terms: One (1) warrant of serie TO 5 B gives you the right to subscribe for one (1) new B-share.
Payment day: 28 February 2023
Market Place: First North Stockholm
Financial Adviser: Sedermera Corporate Finance
Subscribe directly via your bank